eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2008
vol. 3
 
Share:
Share:
more
 
 
abstract:

GIST – risk of recurrence and dissemination

Stanisław Głuszek
,
Rafał Rylski
,
Marta Kot
,
Jerzy Stanisławek
,
Włodzimierz Karcz
,
Antoinette Urbaniak
,
Zbigniew Sosnowski
,
Bohdan Chmielnicki
,
Jerzy Błoński
,
Krzysztof Czerwonka
,
Adam Kabza
,
Włodzimierz Maciejewski
,
Marian Komendacki

Przegląd Gastroenterologiczny 2008; 3 (4): 176–184
Online publish date: 2008/09/05
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

Introduction: GIST (gastrointestinal stromal tumours) are a rare disease constituting less than 1% of digestive tract tumours. Approximately 30% of GIST show features of malignancy with infiltration and metastases.

Aim: Evaluation of patients subjected to surgical management due to GIST tumours. Treatment outcomes, probability of recurrence or dissemination are assessment criteria.

Material and methods: The study group comprised 55 patients, 26 men and 29 women, aged between 43 and 89 (M 44-83, average 66.6; W 43-89, average 66.6) subjected to surgical treatment. Analysis included tumour localization, malignancy, type of surgery, number of recurrences or disseminations and deaths.

Results: 37 patients had gastric tumours (W-25, M-12), 2 (M) duodenal tumours, 12 (M-7, W-4) small intestine tumours, 2 (M) colonic tumours, 2 (M) rectal tumours. 51 patients were operated radically, which was confirmed on histopathological examination. One patient had disseminated disease. 33 patients were found to develop tumours of ≥5 cm, 20 patients with high degree of malignancy, 8 with medium and others with low degree of malignancy. No significant complications were recorded during the postoperative course. 15 patients died during follow-up, 4 due to dissemination of
disease. In 3 cases we noticed recurrence of disease; 1 liver metastasis, 1 bone metastasis and liver metastasis, and one small pelvis tumour. Both deaths due to dissemination and recurrences of disease were associated with high malignancy tumours (diameter >5 cm, IM >5/50 HPF).

Conclusions: Diameter of tumour >5 cm and high mitotic index (IM >5/50 HPF) are the main factors associated with bad outcome (dissemination, recurrence). In the majority of patients with recurrence of disease and dissemination, treated with imatinib, stabilization or regression of disease was observed with good quality of life.
keywords:

GIST – gastrointestinal stromal tumours, surgical treatment, imatinib mesylate

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe